depression with semaglutide and Risk: Clinical Facts Study links semaglutide and tirzepatide

The world of obesity treatment is moving fast

found that there were more HHF patients in the saxagliptin group than in the placebo group, and saxagliptin did not increase the occurrence of ischemic events in patients with HF [99]

Retatrutide itself is still being studied, but approved incretin therapies can require careful glucose monitoring when used with diabetes medications that lower blood sugar

The Canadian context adds specific dimensions to weight-related anxiety

This may indicate a need for dose adjustment, not just management

NAD+ Injectable Therapy Supports cellular energy, improves mental clarity, and boosts recovery and resilience